4-Substituted-1,2,3-triazolo nucleotide analogues as CD73 inhibitors, their synthesis, in vitro screening, kinetic and in silico studies
Copyright © 2021 Elsevier Inc. All rights reserved..
Three series of nucleotide analogues were synthesized and evaluated as potential CD73 inhibitors. Nucleobase replacement consisted in connecting the appropriate aromatic or purine residues through a triazole moiety that is generated from 1,3-dipolar cycloaddition. The first series is related to 4-substituted-1,2,3-triazolo-β-hydroxyphosphonate ribonucleosides. Additional analogues were also obtained, in which the phosphonate group was replaced by a bisphosphonate pattern (P-C-P-C, series 2) or the ribose moiety was removed leading to acyclic derivatives (series 3). The β-hydroxyphosphonylphosphonate ribonucleosides (series 2) were found to be potent inhibitors of CD73 using both purified recombinant protein and cell-based assays. Two compounds (2a and 2b) that contained a bis(trifluoromethyl)phenyl or a naphthyl substituents proved to be the most potent inhibitors, with IC50 values of 4.8 ± 0.8 µM and 0.86 ± 0.2 µM, compared to the standard AOPCP (IC50 value of 3.8 ± 0.9 µM), and were able to reverse the adenosine-mediated immune suppression on human T cells. This series of compounds illustrates a new type of CD73 inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
Bioorganic chemistry - 107(2021) vom: 15. Feb., Seite 104577 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghoteimi, Rayane [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.09.2021 Date Revised 06.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bioorg.2020.104577 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320137287 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320137287 | ||
| 003 | DE-627 | ||
| 005 | 20231225172935.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bioorg.2020.104577 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320137287 | ||
| 035 | |a (NLM)33450542 | ||
| 035 | |a (PII)S0045-2068(20)31875-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghoteimi, Rayane |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 4-Substituted-1,2,3-triazolo nucleotide analogues as CD73 inhibitors, their synthesis, in vitro screening, kinetic and in silico studies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.09.2021 | ||
| 500 | |a Date Revised 06.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a Three series of nucleotide analogues were synthesized and evaluated as potential CD73 inhibitors. Nucleobase replacement consisted in connecting the appropriate aromatic or purine residues through a triazole moiety that is generated from 1,3-dipolar cycloaddition. The first series is related to 4-substituted-1,2,3-triazolo-β-hydroxyphosphonate ribonucleosides. Additional analogues were also obtained, in which the phosphonate group was replaced by a bisphosphonate pattern (P-C-P-C, series 2) or the ribose moiety was removed leading to acyclic derivatives (series 3). The β-hydroxyphosphonylphosphonate ribonucleosides (series 2) were found to be potent inhibitors of CD73 using both purified recombinant protein and cell-based assays. Two compounds (2a and 2b) that contained a bis(trifluoromethyl)phenyl or a naphthyl substituents proved to be the most potent inhibitors, with IC50 values of 4.8 ± 0.8 µM and 0.86 ± 0.2 µM, compared to the standard AOPCP (IC50 value of 3.8 ± 0.9 µM), and were able to reverse the adenosine-mediated immune suppression on human T cells. This series of compounds illustrates a new type of CD73 inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 5′-ectonucleotidase | |
| 650 | 4 | |a Bis-phosphonate | |
| 650 | 4 | |a Click chemistry | |
| 650 | 4 | |a Enzyme inhibitor | |
| 650 | 4 | |a Immuno-oncology | |
| 650 | 4 | |a Nucleotide | |
| 650 | 7 | |a GPI-Linked Proteins |2 NLM | |
| 650 | 7 | |a Nucleotides |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 650 | 7 | |a 5'-Nucleotidase |2 NLM | |
| 650 | 7 | |a EC 3.1.3.5 |2 NLM | |
| 650 | 7 | |a NT5E protein, human |2 NLM | |
| 650 | 7 | |a EC 3.1.3.5 |2 NLM | |
| 700 | 1 | |a Braka, Abdennour |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Cros-Perrial, Emeline |e verfasserin |4 aut | |
| 700 | 1 | |a Tai Nguyen, Van |e verfasserin |4 aut | |
| 700 | 1 | |a Uttaro, Jean-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Mathé, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Chaloin, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Ménétrier-Caux, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Jordheim, Lars Petter |e verfasserin |4 aut | |
| 700 | 1 | |a Peyrottes, Suzanne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioorganic chemistry |d 1986 |g 107(2021) vom: 15. Feb., Seite 104577 |w (DE-627)NLM012846570 |x 1090-2120 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2021 |g day:15 |g month:02 |g pages:104577 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bioorg.2020.104577 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2021 |b 15 |c 02 |h 104577 | ||